STOCK TITAN

biote (BTMD) director awarded 130,000 options and deferred RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

biote Corp. director Debra L. Morris reported compensation-related equity activity. She exercised derivative rights tied to Deferred Settlement RSUs into 21,407 shares of Class A Common Stock and now directly holds 71,562 common shares. She also received awards of 130,000 stock options with a $2.20 exercise price, expiring in 2036, and 39,036 Deferred Settlement RSUs that are fully vested but settle at future dates as described in the award terms.

Positive

  • None.

Negative

  • None.
Insider MORRIS DEBRA L
Role null
Type Security Shares Price Value
Exercise Deferred Settlement RSU 21,407 $0.00 --
Grant/Award Deferred Settlement RSU 39,036 $0.00 --
Grant/Award Stock Option (Right to Buy) 130,000 $0.00 --
Exercise Class A Common Stock 21,407 $0.00 --
Holdings After Transaction: Deferred Settlement RSU — 0 shares (Direct, null); Stock Option (Right to Buy) — 130,000 shares (Direct, null); Class A Common Stock — 71,562 shares (Direct, null)
Footnotes (1)
  1. Each Deferred Settlement RSU is the economic equivalent of one share of Issuer Class A Common Stock. The Deferred Settlement RSUs are fully vested upon grant, but settlement will be deferred until the earlier of calendar year 2026 or the date of the Reporting Person's separation from service. The Deferred Settlement RSUs are fully vested upon grant, but settlement will be deferred until the earlier of calendar year 2027 or the date of the Reporting Person's separation from service. All shares subject to the option award shall vest on the earlier of May 12, 2027 or the day prior to the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date.
RSU-derived shares acquired 21,407 shares Class A Common Stock from Deferred Settlement RSU exercise on May 12, 2026
Shares held after transactions 71,562 shares Direct holdings of Class A Common Stock after Form 4 transactions
Stock options granted 130,000 options Right to buy Class A Common Stock, grant date May 12, 2026
Option exercise price $2.20 per share Strike price for 130,000 stock options
Option expiration May 11, 2036 Expiration date of stock option award
Deferred Settlement RSUs granted 39,036 units Fully vested RSUs economically equivalent to Class A Common Stock
Deferred Settlement RSU financial
"Each Deferred Settlement RSU is the economic equivalent of one share of Issuer Class A Common Stock."
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with an exercise price of 2.2000 per share."
Exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
Class A Common Stock financial
"security_title: Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
fully vested upon grant financial
"The Deferred Settlement RSUs are fully vested upon grant, but settlement will be deferred"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MORRIS DEBRA L

(Last)(First)(Middle)
C/O BIOTE CORP.
1875 W. WALNUT HILL LN #100

(Street)
IRVING TEXAS 75038

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
biote Corp. [ BTMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock05/12/2026M21,407A(1)71,562D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Deferred Settlement RSU(1)05/12/2026M21,407 (2) (2)Class A Common Stock21,407$0.000.00D
Deferred Settlement RSU(1)05/12/2026A39,036 (3) (3)Class A Common Stock39,036$0.0039,036D
Stock Option (Right to Buy)$2.205/12/2026A130,000 (4)05/11/2036Class A Common Stock130,000$0.00130,000D
Explanation of Responses:
1. Each Deferred Settlement RSU is the economic equivalent of one share of Issuer Class A Common Stock.
2. The Deferred Settlement RSUs are fully vested upon grant, but settlement will be deferred until the earlier of calendar year 2026 or the date of the Reporting Person's separation from service.
3. The Deferred Settlement RSUs are fully vested upon grant, but settlement will be deferred until the earlier of calendar year 2027 or the date of the Reporting Person's separation from service.
4. All shares subject to the option award shall vest on the earlier of May 12, 2027 or the day prior to the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date.
Remarks:
/s/ Kendal McNeely, as Attorney-in-Fact for Debra L. Morris05/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Debra L. Morris report at biote (BTMD)?

Debra L. Morris reported exercising derivative rights linked to Deferred Settlement RSUs into 21,407 shares of Class A Common Stock and receiving grants of 130,000 stock options and 39,036 Deferred Settlement RSUs. These are compensation-related awards, not open-market stock purchases or sales.

How many biote (BTMD) shares does Debra L. Morris hold after this Form 4?

After the reported transactions, Debra L. Morris directly holds 71,562 shares of biote Class A Common Stock. This figure reflects her position following the conversion of 21,407 Deferred Settlement RSUs into common shares, as disclosed in the Form 4 filing.

What are the terms of the 130,000 stock options granted to Debra L. Morris at biote?

Debra L. Morris received 130,000 stock options with a $2.20 exercise price, each option representing the right to buy one share of Class A Common Stock. The options expire on May 11, 2036, and vest based on continued service through the vesting date.

What are Deferred Settlement RSUs in the biote (BTMD) Form 4 filing?

Deferred Settlement RSUs are awards economically equivalent to one share of Class A Common Stock each. In this Form 4, 39,036 such RSUs were granted fully vested, but their settlement into shares is deferred to specified future calendar years or the reporting person’s separation from service.

Did Debra L. Morris buy or sell biote (BTMD) shares on the open market?

The Form 4 does not show any open-market purchases or sales. It reports exercises of derivative awards and grants of stock options and Deferred Settlement RSUs, all at a per-share transaction price of $0.00, reflecting compensation-related equity rather than market trades.